Should I buy or sell Allogene Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares. View ALLO analyst ratings or view top-rated stocks .

What is Allogene Therapeutics' stock price target for 2024?

11 brokers have issued 12-month price targets for Allogene Therapeutics' shares. Their ALLO share price targets range from $6.00 to $31.00. On average, they anticipate the company's stock price to reach $15.35 in the next twelve months. This suggests a possible upside of 558.6% from the stock's current price. View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts .

How have ALLO shares performed in 2023?

Allogene Therapeutics' stock was trading at $6.29 on January 1st, 2023. Since then, ALLO shares have decreased by 63.0% and is now trading at $2.33. View the best growth stocks for 2023 here .

When is Allogene Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our ALLO earnings forecast .

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.16. The company earned $0.04 million during the quarter, compared to analysts' expectations of $0.05 million. Allogene Therapeutics had a negative net margin of 178,954.28% and a negative trailing twelve-month return on equity of 54.03%.

What ETFs hold Allogene Therapeutics' stock?

ETFs with the largest weight of Allogene Therapeutics (NASDAQ:ALLO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , Direxion Moonshot Innovators ETF (MOON) , Simplify Propel Opportunities ETF (SURI) , Range Cancer Therapeutics ETF (CNCR) , iShares Genomics Immunology and Healthcare ETF (IDNA) , Global X Genomics & Biotechnology ETF (GNOM) , Horizon Kinetics Medical ETF (MEDX) and

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com . David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , Inovio Pharmaceuticals (INO) , Pfizer (PFE) , Teladoc Health (TDOC) , AbbVie (ABBV) , Alibaba Group (BABA) , Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP) .

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (14.94%), JPMorgan Chase & Co. (4.11%), Primecap Management Co. CA (3.14%), Rafferty Asset Management LLC (0.54%), Barclays PLC (0.47%) and Charles Schwab Investment Management Inc. (0.47%). Insiders that own company stock include Alison Moore, Arie Belldegrun , David D Chang, Eric Thomas Schmidt, Owen N Witte, Owen N Witte , Rafael Amado , Stephen Mayo and Veer Bhavnagri . View institutional ownership trends .

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Allogene Therapeutics Stock Price, News & Analysis (NASDAQ:ALLO)

$2.28

-0.30 (-11.63%)

(As of 04:30 PM ET)

Compare

Today's Range: $2.25
▼
$2.74
50-Day Range: $2.42
▼
$3.91
52-Week Range: $2.25
▼
$10.65

Volume: 4.22 million shs
Average Volume: 2.09 million shs
Market Capitalization: $383.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.35

Allogene Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.64 Rating Score
Upside/Downside: 558.6% Upside
$15.35 Price Target
Short Interest: Bearish
30.59% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.47
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.10) to ($2.00) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

435th out of 949 stocks

Biological Products, Except Diagnostic Industry

72nd out of 161 stocks

3.3

Analyst's Opinion

Consensus Rating
Allogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $15.35, Allogene Therapeutics has a forecasted upside of 558.6% from its current price of $2.33.
Amount of Analyst Coverage
Allogene Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
30.59% of the float of Allogene Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Allogene Therapeutics has a short interest ratio ("days to cover") of 18.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Allogene Therapeutics has recently decreased by 4.97%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Allogene Therapeutics does not currently pay a dividend.
Dividend Growth
Allogene Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALLO.

1.9

News and Social Media Coverage

News Sentiment
Allogene Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Allogene Therapeutics this week, compared to 3 articles on an average week.
Search Interest
8 people have searched for ALLO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Allogene Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
27.40% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
78.51% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Allogene Therapeutics are expected to grow in the coming year, from ($2.10) to ($2.00) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Allogene Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Allogene Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Allogene Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Allogene Therapeutics Stock (NASDAQ:ALLO)

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

ALLO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALLO Stock News Headlines

November 24, 2023 | benzinga.com

Allogene Therapeutics Stock (NASDAQ:ALLO) Dividends: History, Yield and Dates

November 22, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and LAVA Therapeutics (LVTX)

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 22, 2023 | msn.com

Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock

November 19, 2023 | americanbankingnews.com

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 8.5%

November 16, 2023 | markets.businessinsider.com

Allogene Therapeutics Gains Buy Rating: Strong Q3 Financials, Promising Clinical Trials and Catalysts Ahead

November 10, 2023 | finance.yahoo.com

Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know

November 6, 2023 | markets.businessinsider.com

Maintaining Buy Rating on Allogene Therapeutics: Encouraging Financials, Pipeline, and Therapeutic Potential

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 6, 2023 | markets.businessinsider.com

Hold Rating for Allogene Therapeutics Amid Clinical Trials Progress and Financial Concerns

November 4, 2023 | markets.businessinsider.com

Promising Clinical Trials and Innovative Strategies Bolster Buy Rating for Allogene Therapeutics: An Analysis by John Newman

November 3, 2023 | finanznachrichten.de

Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

November 3, 2023 | markets.businessinsider.com

Promising Clinical Trials and Future Market Potential Drive Buy Rating for Allogene Therapeutics

November 3, 2023 | msn.com

Allogene shares rally 22% amid Q3 report, medical meeting presentations

November 3, 2023 | finance.yahoo.com

Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss

November 3, 2023 | finance.yahoo.com

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

November 3, 2023 | finance.yahoo.com

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

November 3, 2023 | finance.yahoo.com

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript

November 2, 2023 | finance.yahoo.com

Allogene Therapeutics Inc (ALLO) Reports Q3 2023 Financial Results

November 2, 2023 | finance.yahoo.com

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

November 1, 2023 | benzinga.com

Earnings Outlook For Allogene Therapeutics

November 1, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Allogene Therapeutics's earnings report

October 31, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Viridian Therapeutics (VRDN) and Tenet Healthcare (THC)

October 29, 2023 | finance.yahoo.com

Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Deliver On Growth Plans?

October 26, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Oric Pharmaceuticals (ORIC), Viking Therapeutics (VKTX)

October 16, 2023 | nasdaq.com

Allogene Therapeutics Names Geoffrey Parker CFO

October 16, 2023 | marketwatch.com

Allogene Therapeutics Taps Ex-Tricida Executive for CFO

See More Headlines

Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALLO
CUSIP: N/A
CIK: 1737287
Web: www.allogene.com
Phone: (650) 457-2700
Fax: N/A
Employees: 359
Year Founded: 2018

Price Target and Rating

Average Stock Price Target: $15.35
High Stock Price Target: $31.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +558.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.64
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-332,630,000.00
Net Margins: -178,954.28%
Pretax Margin: -178,954.27%
Return on Equity: -54.03%
Return on Assets: -43.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.58
Quick Ratio: 12.58

Sales & Book Value

Annual Sales: $240,000.00
Price / Sales: 1,633.72
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.47 per share
Price / Book: 0.67

Miscellaneous

Outstanding Shares: 168,280,000
Free Float: 122,169,000
Market Cap: $392.09 million
Optionable: Not Optionable
Beta: 0.83

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Arie S. Belldegrun F.A.C.S. (Age 74)
M.D., Co-Founder & Executive Chairman
Comp: $714.25k
Dr. David D. Chang M.D. (Age 63)
Ph.D., Co-Founder, President, CEO & Director
Comp: $1.1M
Mr. Joshua A. Kazam (Age 46)
Co-Founder & Director
Comp: $711k
Mr. Geoffrey M. Parker (Age 58)
Executive VP & CFO
Mr. Timothy L. Moore Ph.D. (Age 62)
Executive VP & Chief Technical Officer
Mr. Earl M. Douglas Esq. (Age 60)
General Counsel & Compliance Officer
Ms. Susan R. Lundeen (Age 57)
Chief People Officer
Ms. Christine Cassiano
Executive VP, Chief Corporate Affairs & Brand Strategy Officer
Dr. Zachary J. Roberts M.D. (Age 45)
Ph.D., Executive VP of Research & Development and Chief Medical Officer
Yinlin Chen
Senior Vice President of Finance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALLO Stock Analysis - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares.
View ALLO analyst ratings or view top-rated stocks.
What is Allogene Therapeutics' stock price target for 2024?: 11 brokers have issued 12-month price targets for Allogene Therapeutics' shares. Their ALLO share price targets range from $6.00 to $31.00. On average, they anticipate the company's stock price to reach $15.35 in the next twelve months. This suggests a possible upside of 558.6% from the stock's current price.
View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts.
How have ALLO shares performed in 2023?: Allogene Therapeutics' stock was trading at $6.29 on January 1st, 2023. Since then, ALLO shares have decreased by 63.0% and is now trading at $2.33.
View the best growth stocks for 2023 here.
When is Allogene Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ALLO earnings forecast.
How were Allogene Therapeutics' earnings last quarter?: Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.16. The company earned $0.04 million during the quarter, compared to analysts' expectations of $0.05 million. Allogene Therapeutics had a negative net margin of 178,954.28% and a negative trailing twelve-month return on equity of 54.03%.
What ETFs hold Allogene Therapeutics' stock?: ETFs with the largest weight of Allogene Therapeutics (NASDAQ:ALLO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion Moonshot Innovators ETF (MOON), Simplify Propel Opportunities ETF (SURI), Range Cancer Therapeutics ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX) and

What is David Chang's approval rating as Allogene Therapeutics' CEO?: 2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Allogene Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).
When did Allogene Therapeutics IPO?: (ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.
Who are Allogene Therapeutics' major shareholders?: Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (14.94%), JPMorgan Chase & Co. (4.11%), Primecap Management Co. CA (3.14%), Rafferty Asset Management LLC (0.54%), Barclays PLC (0.47%) and Charles Schwab Investment Management Inc. (0.47%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri.
View institutional ownership trends.
How do I buy shares of Allogene Therapeutics?: Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALLO) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Allogene Therapeutics Stock Price, News & Analysis (NASDAQ:ALLO)

Allogene Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Allogene Therapeutics Stock (NASDAQ:ALLO)

ALLO Stock Price History

ALLO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ALLO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™